16.01.2013 • News

Lonza, BaroFold Announce Technology Evaluation Agreement for PreEMT

Lonza, a leader in biological development and BaroFold, an protein technology developer, announced today a non-exclusive technology and license agreement whereby Lonza will evaluate BaroFold's PreEMT high pressure refolding technology for use in biological development refolding processes. Lonza's evaluation will focus on refolding difficult to express microbial products expressed as inclusion bodies. The PreEMT unit will be installed for evaluation at Lonza's microbial development and manufacturing plant in Visp, Switzerland.

The agreement includes an option for Lonza to extend the platform evaluation to GMP production analysis.

 

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.